Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

8 arms have a reported figure in this set.

B7-H4-directed ADC 2

MYB mRNA degrader 2

REM-422

REM-422 24 mg (RP2D), biomarker positive

24 mg · Single arm

R/M ACC, MYB biomarker positive at RP2D (n = 7)

disease control rate: 100%, ASCO 2026

ARIA · NCT06118086

REM-422

REM-422 12 mg or more, biomarker positive

12 to 48 mg · Single arm

biomarker-positive R/M ACC (n = 30)

any target-lesion reduction: 70%, cutoff 01.07.2026

target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026

ARIA · NCT06118086

MYB splicing modulator 1

RGT-61159

RGT-61159 at or below RP2D

at or below RP2D (mixed doses) · Single arm

R/R ACC, evaluable (n = 39)

disease control rate: 84.6%, ASCO 2026, preliminary

RGT-61159 Phase 1a/b · NCT06462183

VEGFR TKI 2

VEGFR2 TKI 1

Rivoceranib

Rivoceranib 700 mg

700 mg · Single arm

R/M ACC (n = 80; 72 evaluable)

median duration of response (investigator): 14.9 months, primary analysis

Rivoceranib Phase 2 · NCT04119453

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.